HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells
- PMID: 28536404
- PMCID: PMC5344228
- DOI: 10.3390/biomedicines3010138
HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells
Abstract
Hepatocyte growth factor (HGF)-signaling via Met can induce mitogenic, morphogenic, and motogenic activity in various cell types. Met expression in the immune system is limited to cells with antigen-presenting capacities, including dendritic cells (DCs). Thus, it appears highly conceivable that Met-signaling impacts on adaptive immune responses. However, the mechanisms by which HGF imparts its effects on immunological responses are not yet fully understood. DCs possess unique functionalities that are critically involved in controlling both tolerance and immunity. HGF conveys immunoregulatory functions, which strongly correlate with that of DCs orchestrating the apt immune response in inflammation. Therefore, this review focuses on the current knowledge of Met-signaling in DCs with specific emphasis on the morphogenic and motogenic activities. HGF has been identified to play a role in peripheral immune tolerance by directing DC differentiation towards a tolerogenic phenotype. In skin immunity, Met-signaling was shown to drive mobilization of DCs by regulating matrix metalloproteinase activities. This is strikingly reminiscent of the role of Met for regulating a cell fate program during embryonic development, wound healing, and in tumor invasion known as epithelial-mesenchymal transition (EMT). Thus, the concept emerges that an EMT program is executed by Met-signaling in DCs, which will be also discussed.
Keywords: HGF; Langerhans cells; MMPs; Met; dendritic cells; epithelial-mesenchymal transition; immune tolerance; immune-based therapies; migration.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor/Met on Skin Immunity by Modulating Langerhans Cell Migration.Front Immunol. 2018 Mar 16;9:517. doi: 10.3389/fimmu.2018.00517. eCollection 2018. Front Immunol. 2018. PMID: 29616031 Free PMC article. Review.
-
The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity.J Immunol. 2012 Aug 15;189(4):1699-707. doi: 10.4049/jimmunol.1200729. Epub 2012 Jul 16. J Immunol. 2012. PMID: 22802413
-
Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury.Stem Cell Res Ther. 2019 Dec 4;10(1):372. doi: 10.1186/s13287-019-1488-2. Stem Cell Res Ther. 2019. PMID: 31801626 Free PMC article.
-
The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions.Cytokine. 2016 Jun;82:125-39. doi: 10.1016/j.cyto.2015.12.013. Epub 2016 Jan 25. Cytokine. 2016. PMID: 26822708 Review.
-
Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.Anticancer Res. 2015 Apr;35(4):1967-76. Anticancer Res. 2015. PMID: 25862849
Cited by
-
The Occurrence of MET Ectodomain Shedding in Oral Cancer and Its Potential Impact on the Use of Targeted Therapies.Cancers (Basel). 2022 Mar 15;14(6):1491. doi: 10.3390/cancers14061491. Cancers (Basel). 2022. PMID: 35326642 Free PMC article.
-
The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor/Met on Skin Immunity by Modulating Langerhans Cell Migration.Front Immunol. 2018 Mar 16;9:517. doi: 10.3389/fimmu.2018.00517. eCollection 2018. Front Immunol. 2018. PMID: 29616031 Free PMC article. Review.
-
MET Receptor Tyrosine Kinase Inhibition Reduces Interferon-Gamma (IFN-γ)-Stimulated PD-L1 Expression through the STAT3 Pathway in Melanoma Cells.Cancers (Basel). 2023 Jun 29;15(13):3408. doi: 10.3390/cancers15133408. Cancers (Basel). 2023. PMID: 37444518 Free PMC article.
-
The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System.Cells. 2019 May 15;8(5):460. doi: 10.3390/cells8050460. Cells. 2019. PMID: 31096701 Free PMC article. Review.
-
Brain Metastases from Lung Cancer: Is MET an Actionable Target?Cancers (Basel). 2019 Feb 26;11(3):271. doi: 10.3390/cancers11030271. Cancers (Basel). 2019. PMID: 30813513 Free PMC article. Review.
References
-
- Weidner K.M., Arakaki N., Hartmann G., Vandekerckhove J., Weingart S., Rieder H., Fonatsch C., Tsubouchi H., Hishida T., Daikuhara Y., et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. USA. 1991;88:7001–7005. doi: 10.1073/pnas.88.16.7001. - DOI - PMC - PubMed
-
- Sonnenberg E., Meyer D., Weidner K.M., Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-Met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J. Cell Biol. 1993;123:223–235. doi: 10.1083/jcb.123.1.223. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous